biostudies-literatureUnknown49(13)Ruigrok EAMAdvanced Accelerator Applications<h4>Purpose</h4>The radiolabeled gastrin-releasing peptide receptor (GRPR)-targeting antagonist NeoB is a promising radioligand for imaging and therapy of GRPR-expressing malignancies. In the current study, we aimed to discover the target organs of toxicity and the radiotoxic effects to these organs, when repeated dosages of [¹⁷⁷Lu]Lu-NeoB are administered to healthy female and male mice.<h4>Methods</h4>Animals received either 3 injections, with a 7-day interval, of vehicle (control group 1), 1200 pmol [¹⁷⁵Lu]Lu-NeoB (control group 2) or 40 MBq/400 pmol, 80 MBq/800 pmol, and 120 MBq/1200 pmol [¹⁷⁷Lu]Lu-NeoB (treatment groups 1, 2, and 3, respectively). At week 5, 19, and 43 after the first injection acute, early, and late organ toxicity, respectively, was dEuropean journal of nuclear medicine and molecular imaging4440-4451https://www.ebi.ac.uk/biostudies/studies/S-EPMC9605926biostudies-literatureSafety of [¹⁷⁷Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity.PMC9605926de Jong MDalm SUKonijnenberg MWRolfo KStuurman DCde Blois EVerhoeven Mde Ridder CMABertarione LRuigrok EAMfalseSafety of [¹⁷⁷Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity.<h4>Purpose</h4>The radiolabeled gastrin-releasing peptide receptor (GRPR)-targeting antagonist NeoB is a promising radioligand for imaging and therapy of GRPR-expressing malignancies. In the current study, we aimed to discover the target organs of toxicity and the radiotoxic effects to these organs, when repeated dosages of [¹⁷⁷Lu]Lu-NeoB are administered to healthy female and male mice.<h4>Methods</h4>Animals received either 3 injections, with a 7-day interval, of vehicle (control group 1), 1200 pmol [¹⁷⁵Lu]Lu-NeoB (control group 2) or 40 MBq/400 pmol, 80 MBq/800 pmol, and 120 MBq/1200 pmol [¹⁷⁷Lu]Lu-NeoB (treatment groups 1, 2, and 3, respectively). At week 5, 19, and 43 after the first injection acute, early, and late organ toxicity, respectively, was d2022-01-01T00:00:00Z2022 Nov2025-04-19T18:52:47.37Z2024-12-04T08:52:39.04ZS-EPMC96059263595108410.1007/s00259-022-05926-2